Puri Aniket, McGoon Michael D, Kushwaha Sudhir S
King George's Medical University, Lucknow, India.
Nat Clin Pract Cardiovasc Med. 2007 Jun;4(6):319-29. doi: 10.1038/ncpcardio0890.
The treatment of pulmonary arterial hypertension--once a lethal condition--has evolved considerably over the past few years as the number of therapeutic options available to treat this disease has increased. In this Review we attempt to summarize the current knowledge of the pathogenesis of pulmonary hypertension, in relation to the therapies presently available and those that could become available in the near future. The use of prostacyclin and its analogs, calcium-channel blockers, endothelin-receptor antagonists and phosphodiesterase type 5 inhibitors is reviewed. Newer concepts, such as the use of combination therapy, and the potential for long-term disease amelioration and improvement of outcomes, are also discussed. The role of supportive care and medications not specific to pulmonary hypertension is also examined. In addition, we review the novel emerging therapies, such as imatinib, fasudil, simvastatin, ghrelin and vasoactive intestinal peptide, which hold therapeutic potential for disease modification as well as treatment of symptoms.
肺动脉高压——曾经是一种致命疾病——在过去几年里有了很大进展，因为可用于治疗这种疾病的治疗选择数量有所增加。在本综述中，我们试图总结目前关于肺动脉高压发病机制的知识，以及当前可用的治疗方法和在不久的将来可能出现的治疗方法。文中回顾了前列环素及其类似物、钙通道阻滞剂、内皮素受体拮抗剂和5型磷酸二酯酶抑制剂的使用情况。还讨论了联合治疗等较新的概念，以及长期改善疾病和改善预后的可能性。此外，还研究了支持性治疗和非特异性治疗肺动脉高压药物的作用。另外，我们回顾了新兴的新型疗法，如伊马替尼、法舒地尔、辛伐他汀、胃饥饿素和血管活性肠肽，这些疗法在疾病改善及症状治疗方面具有治疗潜力。
